Literature DB >> 27299279

Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.

Kjeld Schmiegelow1, Andishe Attarbaschi2, Shlomit Barzilai3, Gabriele Escherich4, Thomas Leth Frandsen5, Christina Halsey6, Rachael Hough7, Sima Jeha8, Motohiro Kato9, Der-Cherng Liang10, Torben Stamm Mikkelsen11, Anja Möricke12, Riitta Niinimäki13, Caroline Piette14, Maria Caterina Putti15, Elizabeth Raetz16, Lewis B Silverman17, Roderick Skinner18, Ruta Tuckuviene19, Inge van der Sluis20, Ester Zapotocka21.   

Abstract

Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects. This is because reported frequencies vary widely across studies, partly because of diverse definitions of toxic effects. Using the Delphi method, 15 international childhood acute lymphoblastic leukaemia study groups assessed acute lymphoblastic leukaemia protocols to address toxic effects that were to be considered by the Ponte di Legno working group. 14 acute toxic effects (hypersensitivity to asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated pancreatitis, arterial hypertension, posterior reversible encephalopathy syndrome, seizures, depressed level of consciousness, methotrexate-related stroke-like syndrome, peripheral neuropathy, high-dose methotrexate-related nephrotoxicity, sinusoidal obstructive syndrome, thromboembolism, and Pneumocystis jirovecii pneumonia) that are serious but too rare to be addressed comprehensively within any single group, or are deemed to need consensus definitions for reliable incidence comparisons, were selected for assessment. Our results showed that none of the protocols addressed all 14 toxic effects, that no two protocols shared identical definitions of all toxic effects, and that no toxic effect definition was shared by all protocols. Using the Delphi method over three face-to-face plenary meetings, consensus definitions were obtained for all 14 toxic effects. In the overall assessment of outcome of acute lymphoblastic leukaemia treatment, these expert opinion-based definitions will allow reliable comparisons of frequencies and severities of acute toxic effects across treatment protocols, and facilitate international research on cause, guidelines for treatment adaptation, preventive strategies, and development of consensus algorithms for reporting on acute lymphoblastic leukaemia treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27299279     DOI: 10.1016/S1470-2045(16)30035-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  57 in total

1.  Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.

Authors:  Franziska Schramm; Udo Zur Stadt; Martin Zimmermann; Norbert Jorch; Arnulf Pekrun; Arndt Borkhardt; Thomas Imschweiler; Holger Christiansen; Jörg Faber; Irene Schmid; Tobias Feuchtinger; Gerhard Beron; Monique L den Boer; Rob Pieters; Martin A Horstmann; Gritta E Janka-Schaub; Gabriele Escherich
Journal:  Blood Adv       Date:  2019-11-26

2.  Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.

Authors:  Emily R Finch; Colton A Smith; Wenjian Yang; Yiwei Liu; Nancy M Kornegay; John C Panetta; Kristine R Crews; Alejandro R Molinelli; Cheng Cheng; Deqing Pei; Laura B Ramsey; Seth E Karol; Hiroto Inaba; John T Sandlund; Monika Metzger; William E Evans; Sima Jeha; Ching-Hon Pui; Mary V Relling
Journal:  Pediatr Blood Cancer       Date:  2019-10-14       Impact factor: 3.167

Review 3.  The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia.

Authors:  Ruairi Wilson; Caroline Osborne; Christina Halsey
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

4.  Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia.

Authors:  Signe Sloth Mogensen; Kjeld Schmiegelow; Kathrine Grell; Birgitte Klug Albertsen; Peder Skov Wehner; Peter Kampmann; Thomas Leth Frandsen
Journal:  Haematologica       Date:  2017-02-16       Impact factor: 9.941

5.  Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.

Authors:  B O Wolthers; T L Frandsen; J Abrahamsson; B K Albertsen; L R Helt; M Heyman; Ó G Jónsson; L T Kõrgvee; B Lund; R A Raja; K K Rasmussen; M Taskinen; M Tulstrup; G E Vaitkevičienė; R Yadav; R Gupta; K Schmiegelow
Journal:  Leukemia       Date:  2016-07-25       Impact factor: 11.528

Review 6.  Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge.

Authors:  Michaela Kuhlen; Marina Kunstreich; Kathinka Krull; Roland Meisel; Arndt Borkhardt
Journal:  Blood Adv       Date:  2017-06-13

7.  Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

Authors:  N Toft; H Birgens; J Abrahamsson; L Griškevičius; H Hallböök; M Heyman; T W Klausen; Ó G Jónsson; K Palk; K Pruunsild; P Quist-Paulsen; G Vaitkeviciene; K Vettenranta; A Åsberg; T L Frandsen; H V Marquart; H O Madsen; U Norén-Nyström; K Schmiegelow
Journal:  Leukemia       Date:  2017-08-18       Impact factor: 11.528

8.  Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.

Authors:  Christopher C Denton; Yasmin A Rawlins; Matthew J Oberley; Deepa Bhojwani; Etan Orgel
Journal:  Pediatr Blood Cancer       Date:  2017-12-08       Impact factor: 3.167

9.  Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia.

Authors:  Marissa A H den Hoed; Saskia M F Pluijm; André G Uitterlinden; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

Review 10.  Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives.

Authors:  Amber Gibson; Carlos Hernandez; Fiorela N Hernandez Tejada; Jitesh Kawedia; Michael Rytting; Branko Cuglievan
Journal:  Paediatr Drugs       Date:  2021-08-05       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.